Seismyc DETECT. DECODE. TRADE. LIVE Pulse
← All stories
Markets 1 sources

Exelixis zanzalintinib NDA review extended three months by FDA

Covered by 1 source · 1 article

Covered by
Seekingalpha

All coverage

Seeking Alpha Currents 1h ago

Exelixis zanzalintinib NDA review extended three months by FDA

More top stories

18m ago Crypto never closes, but Bitcoin, Ethereum, XRP and Solana now move on Wall Street time 18m ago Solana activates second wave of rent reduction, reclaiming 612K SOL 22m ago Metaplanet cuts executive reward pool by 41%, extinguishes $220 million in value 22m ago FxPro Joins Retail Brokers in Weekend Trading Adding Gold, Oil and Nasdaq 23m ago Iranian conservative rift deepens as lawmaker targets President Pezeshkian 24m ago Pound climbs after UK growth beats expectations, powered by AI and tech boom